4-溴-2-氯甲基-1-甲氧基苯 | 7017-52-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-溴-2-氯甲基-1-甲氧基苯
• 英文名称: 4-bromo-2-(chloromethyl)-1-methoxybenzene
• CAS: 7017-52-9
• 化学式: C₈H₈BrClO
• mdl: MFCD08236794
• 分子量: 235.508
• InChiKey: YUJFMJVATVQTBS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2909309090

反应信息

• 作为反应物：
  描述：

  4-溴-2-氯甲基-1-甲氧基苯 在 三氯化铝 、 乙醇 、 苯 作用下， 生成 6-溴苯并二氢吡喃-2-酮
  参考文献：
  名称：

  A Synthesis for 4-Bromo-7-methoxyhydrindene

  摘要：

  DOI：

  10.1021/ja01178a077
• 作为产物：
  描述：

  5-溴-2-甲氧基苯甲醛 在 sodium tetrahydroborate 、 氯化亚砜 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 2.0h， 生成 4-溴-2-氯甲基-1-甲氧基苯
  参考文献：
  名称：

  Cationic Chalcone Antibiotics. Design, Synthesis, and Mechanism of Action

  摘要：

  This paper describes how the introduction of "cationic" aliphatic amino groups in the chalcone scaffold results in potent antibacterial compounds. It is shown that the most favorable position for the aliphatic amino group is the 2-position of the B-ring, in particular in combination with a lipophilic substituent in the 5-position of the beta-ring. We demonstrate that the compounds act by unselective disruption of cell membranes. Introduction of an additional aliphatic amino group in the A-ring results in compounds that are selective for bacterial membranes combined with a high antibacterial activity against both Gram-positive and -negative pathogens. The most potent compound in this study (78) has an MIC value of 2 mu M against methicillin resistant Staphylococus aureus.

  DOI：

  10.1021/jm049424k

文献信息

• A Series of Analogues to the AT₂ R Prototype Antagonist C38 Allow Fine Tuning of the Previously Reported Antagonist Binding Mode
  作者：Rebecka Isaksson、Jens Lindman、Johan Wannberg、Jessica Sallander、Maria Backlund、Dhaniel Baraldi、Robert Widdop、Mathias Hallberg、Johan Åqvist、Hugo Gutierrez de Teran、Johan Gising、Mats Larhed

  DOI：10.1002/open.201800282

  日期：2019.1

  in the first series was equipotent to C38 and showed similar kinetic solubility, and stability in both human and mouse liver microsomes. The second series was comprised of new bicyclic derivatives, amongst which one ligand exhibited a five‐fold improved affinity to AT2R as compared to C38. The majority of the compounds in the second series, including the most potent ligand, were inferior to C38 with

  我们在这里报告我们对配体与有前途的药物靶标血管紧张素 II 2 型受体 (AT 2 R) 结合的持续研究。合成并研究了两个系列的化合物。第一个系列探讨了在已知选择性非肽 AT 2 R 拮抗剂C38的苯环上添加小取代基的影响，从而产生小但显着的 AT 2 R 亲和力变化。第一个系列中的一种化合物与C38等效，并且在人和小鼠肝微粒体中表现出相似的动力学溶解度和稳定性。第二个系列由新的双环衍生物组成，其中一种配体对 AT 2 R 的亲和力比C38提高了五倍。第二系列中的大多数化合物，包括最有效的配体，在人和小鼠微粒体中的稳定性都低于C38 。与我们之前报道的发现相反，具有较短氨基甲酸酯烷基链的配体仅表现出微粒体中稳定性的轻微改善。基于本文提供的数据，提出了配体类似物与原型AT 2 R拮抗剂C38的结合模式的更充分、暂定的模型，如通过分子动力学模拟重新定义的对接推导出来的。
• First Contact: 7-Phenyl-2-Aminoquinolines, Potent and Selective Neuronal Nitric Oxide Synthase Inhibitors That Target an Isoform-Specific Aspartate
  作者：Maris A. Cinelli、Cory T. Reidl、Huiying Li、Georges Chreifi、Thomas L. Poulos、Richard B. Silverman

  DOI：10.1021/acs.jmedchem.9b01573

  日期：2020.5.14

  Inhibition of neuronal nitric oxide synthase (nNOS), an enzyme implicated in neurodegenerative disorders, is an attractive strategy for treating or preventing these diseases. We previously developed several classes of 2-aminoquinoline-based nNOS inhibitors, but these compounds had drawbacks including off-target promiscuity, low activity against human nNOS, and only modest selectivity for nNOS over

  抑制神经元一氧化氮合酶（nNOS）是一种涉及神经退行性疾病的酶，是治疗或预防这些疾病的有吸引力的策略。我们以前开发了几类基于2-氨基喹啉的nNOS抑制剂，但是这些化合物的缺点包括脱靶混杂，对人nNOS的活性低以及对nNOS的选择性比相关酶适度。在这项研究中，我们合成了基于7-苯基-2-氨基喹啉的新型nNOS抑制剂，并针对大鼠和人类nNOS，人类eNOS和鼠类（在某些情况下）对人类iNOS进行了测定。在氨基喹啉和带正电荷的尾部之间具​​有元关系的化合物很有效，对人nNOS的选择性比对人eNOS的选择性高近900倍。X射线晶体学分析表明某些化合物的氨基占据了nNOS特异性天冬氨酸残基（eNOS中不存在）周围充满水的口袋。诱变研究证实了这种相互作用，使7-苯基-2-氨基喹啉成为第一个与该残基相互作用的氨基喹啉。
• Certain aminomethyl biphenyl, aminomethyl phenyl pyridine and
  申请人：Neurogen Corporation

  公开号：US05594141A1

  公开（公告）日：1997-01-14

  Disclosed are compounds of the formula: ##STR1## where S and V are various organic or inorganic substituents; G and K are the same or different and represent N or CR' where R' is an organic or inorganic substituent; R is hydrogen or an alkyl group; R.sub.1, X, Y, Z and T are organic or inorganic substituents; and R.sub.2 and R.sub.3 represent hydrogen or organic substituents; or NR.sub.2 R.sub.3 together represents a heterocyclic ring system; and the pharmaceutically acceptable salts thereof; which are highly selective partial agonists or antagonists at brain dopamine receptor subtypes and, thus, are useful in the diagnosis and treatment of affective disorders such as schizophrenia and depression as well as certain movement disorders such as Parkinsonism.

  揭示的是以下化合物的结构：##STR1## 其中S和V是各种有机或无机取代基；G和K相同或不同，代表N或CR'，其中R'是有机或无机取代基；R是氢或烷基；R.sub.1、X、Y、Z和T是有机或无机取代基；R.sub.2和R.sub.3代表氢或有机取代基；或NR.sub.2 R.sub.3一起代表一个杂环系统；以及其药用可接受的盐；它们是高度选择性的部分激动剂或拮抗剂，在大脑多巴胺受体亚型上，因此，在诊断和治疗情感障碍如精神分裂症和抑郁症以及某些运动障碍如帕金森症方面是有用的。
• Certain methylpiperazinyl and methylpiperidinyl substituted biphenyl
  申请人：Neurogen Corporation

  公开号：US05677454A1

  公开（公告）日：1997-10-14

  Disclosed are compounds of the formula: ##STR1## where S and V are various organic or inorganic substituents; G and K are the same or different and represent N or CR' where R' is an organic or inorganic substituent; R is hydrogen or an alkyl group; R.sub.1, X, Y, Z and T are organic or inorganic substituents; and R.sub.2 and R.sub.3 represent hydrogen or organic substituents; or NR.sub.2 R.sub.3 together represents a heterocyclic ring system; and the pharmaceutically acceptable salts thereof; which are highly selective partial agonists or antagonists at brain dopamine receptor subtypes and, thus, are useful in the diagnosis and treatment of affective disorders such as schizophrenia and depression as well as certain movement disorders such as Parkinsonism.

  本发明揭示了下式化合物：##STR1## 其中，S和V是各种有机或无机取代基；G和K相同或不同，代表N或CR'，其中R'是有机或无机取代基；R是氢或烷基；R.sub.1、X、Y、Z和T是有机或无机取代基；R.sub.2和R.sub.3代表氢或有机取代基；或NR.sub.2R.sub.3一起代表杂环环系统；以及其药学上可接受的盐；这些化合物是高度选择性的部分激动剂或拮抗剂，可用于诊断和治疗情感障碍，如精神分裂症和抑郁症，以及某些运动障碍，如帕金森病。
• Certain aminomethyl biphenyl, aminomethyl phenyl pyridine and aminomethyl phenyl pyrimidine derivatives; novel dopamine receptor subtype selective ligands
  申请人：Neurogen Corporation

  公开号：US06221871B1

  公开（公告）日：2001-04-24

  Disclosed are compounds of the formula: where S and V are various organic or inorganic substituents; G and K are the same or different and represent N or CR′ where R′ is an organic or inorganic substituent; R is hydrogen or an alkyl group; R1, X, Y, Z and T are organic or inorganic substituents; and R2 and R3 represent hydrogen or organic substituents; or NR2R3 together represents a heterocyclic ring system; and the pharmaceutically acceptable salts thereof; which are highly selective partial agonists or antagonists at brain dopamine receptor subtypes and, thus, are useful in the diagnosis and treatment of affective disorders such as schizophrenia and depression as well as certain movement disorders such as Parkinsonism.

  本发明涉及一种化合物，其化学式为：其中S和V是不同的有机或无机取代基；G和K相同或不同，代表N或CR'，其中R'是有机或无机取代基；R是氢或烷基；R1、X、Y、Z和T是有机或无机取代基；R2和R3代表氢或有机取代基；或NR2R3一起代表一个杂环环系统；以及其药学上可接受的盐；该化合物是高度选择性的部分激动剂或拮抗剂，在大脑多巴胺受体亚型上，因此，在诊断和治疗情感障碍（如精神分裂症和抑郁症）以及某些运动障碍（如帕金森症）方面非常有用。